Biotec Pharmacon aims to increase the value of the Biotec Pharmacon share through long-term profitable commercialization of its specialized bio-active products, as well as through licensing revenues from commercial partners.
The company gives priority, therefore, to provide current information to the stock market about the company’s development in order to give shareholders the best possible basis for assessing the value of its shares at any time.
The company is currently in a development phase for its medicinal products. Within the marine biochemicals, the company plans to invest in strengthening its marketing capacity. In the short term, the cost of operations will exceed the revenues. There are no plans for dividend to shareholders in the short to medium term.